CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 1,931,497	$ 5,389,089
Cost of revenues	720,900	877,613
Operating expenses:
Selling, general and administrative	10,138,103	10,278,045
Research and development	3,321,763	2,967,278
Depreciation and amortization	285,730	390,424
Total operating expenses	13,745,596	13,635,747
LOSS FROM OPERATIONS	(12,534,999)	(9,124,271)
Other (expense) income:
Interest expense (including related party interest of $46,586 for the year ended September 30, 2019)	(115,830)	(162,432)
Other expense, net	(378,075)	(43,299)
Loss on extinguishment of debt	0	(1,260,399)
Unrealized gain on change in fair value of secured convertible notes payable	0	1,972,955
Loss before provision for income taxes	(13,028,904)	(8,617,446)
Provision for income taxes	0	15,000
NET LOSS	(13,028,904)	(8,632,446)
Less: Net loss (income) attributable to noncontrolling interest	1,685	9,323
NET LOSS attributable to Applied DNA Sciences, Inc.	(13,027,219)	(8,623,123)
Deemed dividend related to warrant modifications	2,842	(309,607)
NET LOSS applicable to common stockholders	$ (13,030,061)	$ (8,932,730)
Net loss per share applicable to common stockholders-basic and diluted	$ (3.32)	$ (9.69)
Weighted average shares outstanding-basic and diluted (in shares)	3,919,072	921,809
Product
Revenues:
Total revenues	$ 615,430	$ 2,136,055
Service
Revenues:
Total revenues	$ 1,316,067	$ 3,253,034